Merck Receives Approval from FDA for Expanded Indications for
Atypical Antipsychotic Medication Saphris
From the PharmaLive.com News Archive - Sep. 07, 2010
Merck today announced that the FDA has approved two sNDA's for
Saphris (asenapine) sublingual tablets to expand the product's
indications. Saphris is now indicated for the treatment of
schizophrenia in adults, as monotherapy for the acute treatment of
manic or mixed episodes associated with bipolar I disorder in adults,
and as adjunctive therapy with either lithium or valproate for the
acute treatment of manic or mixed episodes associated with bipolar I
disorder in adults.
www.peoplewho.org